Drugs / DS-3939a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05875168 | Aug 2023 → Oct 2026 expected | metastatic neoplasm, neoplasm | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-3939a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05875168 ↗ |
| Route | Intravenous | “intravenous (IV) infusion of DS-3939a” NCT05875168 ↗ |
| Target | MUC1 | “DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd” PMID 40635151 ↗ Jan 2026 |